Compare Regeneron Pharmaceuticals Inc (REGN) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $750.28 (market cap $76.14B), while Invesco S&P 500 High Div Low Volatility ETF trades at $48.73 (market cap $3.14B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 24.2× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while Invesco S&P 500 High Div Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and Invesco S&P 500 High Div Low Volatility ETF for 125 Days on average.
| REGN | SPHD | |
|---|---|---|
Market Cap | $76.14B | $3.14B |
Volume | 500,239 | 1,461,349 |
Sector | Health | — |
52-Week High | $852.03 | $53.55 |
52-Week Low | $557.73 | $46.96 |
Typical Hold Time | 107 Days | 125 Days |
Enterprise Value | $70.85B | — |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.28, down 0.38% on the day, with a bearish technical signal and neutral oscillators. The company shows strong fundamentals with a P/E of 18.3, net income margin of 27.86%, and consistent earnings beats in recent quarters. Recent news highlights a major $8 billion immunology alliance expansion with Sanofi, including a $1 billion upfront payment, reinforcing its pipeline strength and long-term growth prospects.
The outlook remains positive driven by robust profitability, strategic collaborations, and a bullish analyst consensus with a $849.84 price target. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. Institutional sentiment is strong with no sell ratings, supporting a favorable risk-reward profile for investors seeking exposure to biopharmaceutical innovation.
SPHD trades at $48.72 with a 1.1% daily gain, but technical indicators show a bearish trend with moving averages signaling strong selling pressure. The ETF's monthly dividend structure provides consistent income, though recent analysis highlights underperformance compared to peers like SCHD over the past decade. Key support sits at $47 with resistance at $49.
The outlook remains cautious given bearish technical signals and competitive pressure from higher-performing dividend ETFs. While monthly dividends appeal to income-focused investors, SPHD's lack of quality screening exposes it to yield traps. Near-term performance depends on market volatility and dividend sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
